Audiologists' perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey.
Audiologists' perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey.
复制标题
DOI：
10.1007/s11764-022-01316-7
复制
发表时间：
2023-03
影响因子：
3.7
通讯作者：
Clark, Khaya D.
中科院分区：
文献类型：
--
作者：
Konrad-Martin, Dawn;Polaski, Rachel;DeBacker, J. Riley;Theodoroff, Sarah M.;Garinis, Angela;Lacey, Cecilia;Johansson, Kirsten;Mannino, Rosemarie;Milnes, Trisha;Hungerford, Michelle;Clark, Khaya D.
关键词：
用于治疗许多类型癌症的铂基化疗药物具有耳毒性。减轻癌症幸存者耳毒性结局的耳毒性管理（OtoM）是推荐的实践，但它不是肿瘤护理的标准部分。虽然每年有超过10，000名患者在美国退伍军人健康管理局（VA）接受铂类化疗，但VA中OtoM的当前状态尚未明确。本研究报告的VA听力学家对OtoM在癌症患者的看法全国调查。一个26项在线调查管理的VA听力学家和服务负责人在VA的18个地区的护理系统。数据分析采用描述性统计和演绎主题分析。61名受访者包括至少一名来自每个VA地区。所有人都报告说，他们认为某种形式的OtoM对高危癌症患者是必要的。治疗前基线、早期检测耳毒性的能力以及治疗期间和治疗后耳毒性效应的管理被受访者认为是OtoM的高价值目标。大约一半的人报告说，他们经常为接受顺铂和卡铂的患者提供这些服务。受访者对适当的听力测试时间表以及如何共同管理OtoM与肿瘤学的职责存在分歧。他们确定了符合三个主题的护理障碍：与肿瘤学的护理和转诊协调，听力学工作量以及缺乏协议。虽然VA听力学家重视为癌症患者提供OtoM，但只有大约一半的人在高耳毒性治疗方案中使用OtoM。OtoMIC调查提供了临床医生的观点，以基准和解决OtoM护理差距。需要肿瘤学和听力学之间的合作来改善当前的OtoM过程，以便癌症幸存者可以更好地控制他们的长期听力健康。在线版本包含补充材料，可通过10.1007/s11764-022-01316-7获得。
Platinum-based chemotherapies used to treat many types of cancers are ototoxic. Ototoxicity management (OtoM) to mitigate the ototoxic outcomes of cancer survivors is recommended practice yet it is not a standard part of oncologic care. Although more than 10,000 patients each year are treated with platinum-based chemotherapies at the US Veterans Health Administration (VA), the current state of OtoM in VA is not well-defined. This study reports on a national survey of VA audiologists’ perceptions regarding OtoM in cancer patients. A 26-item online survey was administered to VA audiologists and service chiefs across the VA’s 18 regional systems of care. Descriptive statistics and deductive thematic analysis were used to analyze the data. The 61 respondents included at least one from each VA region. All reported they felt some form of OtoM was necessary for at-risk cancer patients. A pre-treatment baseline, the ability to detect ototoxicity early, and management of ototoxic effects both during and after treatment were considered high value objectives of OtoM by respondents. Roughly half reported routinely providing these services for patients receiving cisplatin and carboplatin. Respondents disagreed regarding appropriate hearing testing schedules and how to co-manage OtoM responsibilities with oncology. They identified barriers to care that conformed to three themes: care and referral coordination with oncology, audiology workload, and lack of protocols. Although VA audiologists value providing OtoM for cancer patients, only about half perform OtoM for highly ototoxic treatment regimens. The OtoMIC survey provides clinician perspectives to benchmark and address OtoM care gaps. Collaboration between oncology and audiology is needed to improve current OtoM processes, so that cancer survivors can have more control over their long term hearing health. The online version contains supplementary material available at 10.1007/s11764-022-01316-7.
登录
查看更多内容
DOI：
10.1186/1748-5908-4-50
发表时间：
2009-08-07
期刊：
Implementation science : IS
影响因子：
--
作者：
Damschroder LJ;Aron DC;Keith RE;Kirsh SR;Alexander JA;Lowery JC
通讯作者：
Lowery JC
影响因子：
3.7
作者：
Ardeshirrouhanifard, Shirin;Fossa, Sophie D.;Huddart, Robert;Monahan, Patrick O.;Fung, Chunkit;Song, Yiqing;Dolan, M. Eileen;Feldman, Darren R.;Hamilton, Robert J.;Vaughn, David;Martin, Neil E.;Kollmannsberger, Christian;Dinh, Paul;Einhorn, Lawrence;Frisina, Robert D.;Travis, Lois B.
通讯作者：
Travis, Lois B.
DOI：
10.1056/nejmra1616601
发表时间：
2017-12-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Cunningham LL;Tucci DL
通讯作者：
Tucci DL
影响因子：
7.8
作者：
Falchook, Aaron D.;Green, Rebecca;Chera, Bhishamjit S.
通讯作者：
Chera, Bhishamjit S.
影响因子：
2.6
作者：
Dillard, Lauren K.;Lopez-Perez, Lucero;Martinez, Ricardo X.;Fullerton, Amanda M.;Chadha, Shelly;McMahon, Catherine M.
通讯作者：
McMahon, Catherine M.